Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23458146 | 0.89 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3PREP | |
| SCHEMBL23478037 | 0.87 | HSD17B10 (0.48) | HSD17B10CHRM2CHRM1CHRM3PREP | |
| SCHEMBL29097084 | 0.84 | NR1H2 (0.48) | HSD17B10CHRM2CHRM1CHRM3PREP | |
| SCHEMBL23478303 | 0.84 | NR1H2 (0.48) | HSD17B10CHRM2CHRM1CHRM3PREP | |
| SCHEMBL1271995 | 0.83 | HSD17B10 (0.42) | HSD17B10CHRM2CHRM1CHRM3PREP | |
| SCHEMBL1272381 | 0.83 | HSD17B10 (0.42) | HSD17B10CHRM2CHRM1CHRM3PREP | |
| SCHEMBL27059386 | 0.81 | CHRM2 (0.44) | HSD17B10CHRM2CHRM1CHRM3PREP | |
| SCHEMBL25949561 | 0.81 | CHRM2 (0.44) | HSD17B10CHRM2CHRM1CHRM3PREP | |
| SCHEMBL5479849 | 0.81 | NR1H2 (0.44) | HSD17B10EIF2AK4SMN1; SMN2NR1H2LMNA | |
| SCHEMBL29755212 | 0.80 | HSD17B10 (0.48) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114746419-B | N- (3- (5- (pyrimidin-4-yl) thiazol-4-yl) phenyl) sulfonamide compounds and their use as BRAF inhibitors | 国家医疗保健研究所 | 2023-10-24 | — | — | CN | disclosed |
| US-20230036867-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-02-02 | — | — | US | disclosed |
| EP-4069692-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-10-12 | — | — | EP | disclosed |
| CN-114746419-A | N- (3- (5- (pyrimidin-4-yl) thiazol-4-yl) phenyl) sulfonamide compounds and their use as BRAF inhibitors | 国家医疗保健研究所 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021110997-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021110997-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230036867-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | BRAF, RAF1, NRAS | HSD17B10 4556/4885CHRM2 4884/4885CHRM1 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.